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Allograft reinfection with hepatitis C virus (HCV) occurs universally in liver transplant recipients. Corticosteroids can contribute
to HCV recurrence. This randomized study evaluated HCV recurrence in HCV-positive liver allograft recipients using steroid-
free immunosuppression. All patients received tacrolimus (TAC) at an initial dose of 0.10–0.15mg/kg. The steroid-free arm
(TAC/daclizumab (TAC/DAC, n = 67)) received daclizumab induction, and the steroid arm (TAC/steroid (TAC/STR, n = 68))
received a steroid bolus (≤500mg) followed by 15–20mg/day with discontinuation after month 3. Median HCV viral load
at month 12, the primary endpoint, was similar at 5.46 (0.95–6.54)IU/mL with TAC/DAC and 5.91 (0.95–6.89)IU/mL with
TAC/STR. Small numerical diﬀerences in the estimated rate of freedom from HCV recurrence (19.1 versus 13.8%) and freedom
from biopsy proven rejection (78.4 versus 66.1%) were observed between TAC/DAC and TAC/STR. Patient survival estimates were
signiﬁcantly lower with TAC/DAC than with TAC/STR (83.1 versus 95.5%; 95%CI, −0.227 to −0.019%), and graft survival was
numerically lower (80.1 versus 91.1%, P = NS). Completion rates (45 versus 82%) indicated poorer tolerability with TAC/DAC
than with TAC/STR. Steroid-free immunosuppression had no real impact on HCV viral load. HCV recurrence was higher with
TAC/STR. Results are inconclusive due to the unexpected lower completion rates in the TAC/DAC arm.
1.Introduction
Cirrhosis secondary to hepatitis C virus (HCV) is the most
common indication for orthotopic liver transplantation.
Unfortunately,allograftreinfectionwithHCVoccursuniver-
sallyinlivertransplantrecipients.Acuterecurrencecanoccur
within 6 months after transplantation [1], is often more
severe than the primary HCV disease, and leads to fairly
rapid progression to cirrhosis. Recurrent viral infection with
progression to cirrhosis and graft failure is the most frequent
cause of morbidity in the posttransplant setting [2–4].
Factors possibly contributing to the recurrence of HCV
include viral HCV-related factors (viral load and genotype
[5, 6]), coinfection with other viruses, donor-related factors,
type and amount of immunosuppression, and steroid pulses
for treatment of acute rejection [7, 8].
The choice of calcineurin inhibitor does not seem to in-
ﬂuence HCV recurrence [9]. In a prospective randomized
study, no signiﬁcant diﬀerence in HCV recurrence or HCV
progression was found between tacrolimus- and cyclospo-
rine-based treatments [5]. A relationship between steroids
and the severity of HCV recurrence has, however, been2 Journal of Transplantation
observed [10]. Posttransplant tapering of steroids has been
found to reduce the progression of recurrent HCV [11, 12]
while pulse administration of steroids for treatment of acute
rejection has been associated with development of cirrhosis
[13]—a primary cause of graft loss in liver transplantation.
In this study we explored the impact of steroid-free
immunosuppression on HCV viral load at 12 months in
patients transplanted for HCV cirrhosis. The onset of HCV-
related liver disease is diﬃcult to determine as the clinical
signs and symptoms of HCV are similar to those of acute
rejection and the two conditions can coexist [14]. We there-
fore used HCV viral load as a surrogate indicator of HCV
recurrence because of the potential diﬃculty in diﬀerenti-
ating between acute rejection and HCV disease after trans-
plantation. To test the eﬀect of a steroid-free regimen, we
compared two tacrolimus-based protocols: one with steroid
administration for 3 months (the reference treatment) and
the other with daclizumab in which steroids were avoided
for both prophylactic immunosuppression, and wherever
possible, antirejection treatment (experimental treatment):
we assumed that HCV recurrence would be lower with
the steroid avoidance regimen. Safety and eﬃcacy evidence
for omitting steroids [15, 16] and for replacing steroids
with daclizumab [17] in immunosuppression protocols in
liver transplantation has been demonstrated in randomized
multicenter clinical trials.
2. Methods
2.1. Study Design and Patients. This was a prospective, ran-
domized, open-label, parallel arm study that was conducted
betweenJune2005andJune2008at17centersin8European
countries. Patients were followed up to 12 months unless
they withdrew consent or withdrew from treatment for
reasons other than death or graft loss. Inclusion criteria
included age above 18 years, hepatitis C virus positive, and
ﬁrst orthotopic (whole or split) liver transplant. Exclusion
criteriawereon-goingsteroidadministration,HIVpositivity,
ABO incompatibility, and a previous history of malignancy
other than treated nonmelanoma skin cancer. Patients with
hepatocellular carcinoma were included unless they had >3
nodules, the nodules were >5cm in diameter, and there was
evidence of vascular invasion, metastases, or local invasion.
The study was conducted in compliance with the Dec-
laration of Helsinki and Good Clinical Practice guidelines
andinaccordancewithlocalandnationalregulatoryrequire-
ments and laws. All relevant study documents were approved
by the Institutional Review Board responsible for the study
center. All patients provided signed informed consent and
could withdraw from the study at any time.
2.2. Treatment Intervention. Tacrolimus was administered to
patients in both treatment arms. The initial daily dose was
0.10–0.15mg/kg. Recommended trough levels from day 0
today 42 were 10–15ng/mL, and from day 43 to day 365
levels were <10ng/mL.
The experimental treatment protocol was tacrolimus and
daclizumab (TAC/DAC). Two doses of daclizumab 2.0mg/kg
were administered; the ﬁrst dose was given during the
anhepaticperiodandtheseconddosebetweendays7and10.
Biopsy conﬁrmed that acute rejection was treated by increas-
ing tacrolimus dose to attain trough levels of 15ng/mL. If
rejectionpersisted,thymoglobulin(RATG)wasadministered
at 1.5mg/kg for up to 3 days; acetaminophen and intra-
venous H1-receptor antagonists could be administered for
premedication against anaphylactic reaction.
The reference treatment protocol was tacrolimus and
steroids (TAC/STR). Steroids were given at a bolus dose of
≤500mg in the perioperative period followed by tapered
doses of 15–20mg/day during month 1, 10–15mg/day dur-
ing month 2, 5–10mg/day during month 3, then discontin-
ued. Biopsy conﬁrmed that acute rejection was treated by
increasing tacrolimus dose to attain trough levels of 15ng/
mL. If there was no response, pulses of corticosteroids up to
1000mg/day for 3 consecutive days could be administered.
Prophylactic antiviral treatment was required for cyto-
megalovirus (CMV) in cases where a CMV-positive donor
graft was transplanted in a CMV-negative recipient.
Treatment with the following drugs was prohibited dur-
ing the study: any other immunosuppressive agents except
for mycophenolate mofetil (MMF) used at the discretion
of the investigator for rejection treatment and polyclonal
antibodies and OKT3 that were allowed for the treatment of
intractable rejection.
2.3. Outcomes. Viral load of HCV at 12 months was the
studyprimaryendpoint.Quantitativeandasnecessaryquali-
tative serum HCV-RNA evaluations were performed using
branched DNA technology. In cases where a viremia reading
was <3200copies/mL, the TMA method was used as a sensi-
tive analysis to measure copies ≥50/mL. Serum HCV RNA
has been demonstrated to be a reliable indicator of hepatitis
C liver disease [18].
The incidence of and time to hepatitis C recurrence was
evaluated. HCV recurrence was diagnosed by liver biopsy
and was performed as clinically indicated (in patients with
elevated liver enzymes) or at protocol-deﬁned biopsy con-
trol. Recurrence was deﬁned as acute hepatitis with lobular
necroinﬂammatory activity and/or as chronic hepatitis with
lymphoplasmacytic portal inﬂammation with interphase
hepatitis, lobular necroinﬂammatory activity, and with por-
tal ﬁbrosis. The histological grading and staging of biopsies
for HCV evaluation were based on the modiﬁed HAI score
by Ishak et al. [19]. Other outcomes measured were: the
incidence of and time to ﬁrst biopsy-proven acute rejection
(BPAR); patient and graft survival at 12 months; renal
function that was assessed by calculated creatinine clearance
(Cockcroft-Gault formula [20]); the incidence of adverse
events that were classiﬁed using MedDRA before database
closure. Patients were followed up to 12 months even if
prematurely discontinuing study treatments.
Samples for the evaluation of qualitative and quanti-
tative serum HCV-RNA were collected at baseline and at
subsequent regular assessments. Routine hematology and
blood chemistry were assessed at 9 regular assessment visits
(baseline (day 0, deﬁned as the day of liver transplantation),Journal of Transplantation 3
days 1, 7, and 14, and months 2, 3, 6, 9, and 12) or at the
time of premature study discontinuation. Tacrolimus trough
levels were measured after the ﬁrst dose then 2-3 times
per week during the period of hospitalization and at each
scheduled follow-up out-patient visit or more frequently
if clinically indicated. Protocol biopsies were performed
at the end of months 6 and 12; central assessment of
biopsy specimens was conducted in a blinded manner.
The evaluation of non-protocol-deﬁned biopsies was done
locally.
2.4. Sample Size and Randomization. There were no histori-
cal data on HCV viral load available at the time of the design
of this exploratory study for the planned patient population.
Therefore, sample size was based on a compromise between
the considerations of feasibility and reasonable statistical
power to detect a signal for a positive eﬀect of the avoidance
of steroids on HCV viral load.
Basedona(1-sided)Mann-WhitneyU testandassuming
a standard deviation of 0.6 log10 (copies/mL) the sample size
of 50 evaluable patients per treatment arm was considered
large enough to achieve a power >80%. Assuming a rate of
15% nonevaluable patients, 120 patients (60 per treatment
arm) were to be randomized.
Allocationtotreatmentarmswasperformedusingsealed
sequentially numbered randomization envelopes provided
by the study sponsor. RANCODE (version 3.6) was used
to generate the randomization sequence. Randomization to
treatment was 1:1 with stratiﬁcation by center.
2.5. Statistical Methods. HCV viral load at 12 months was
analyzed after a transformation using log10, which resulted
in the unit log10 (IU/mL). The 1-sided Wilcoxon rank sum
test was used to test for the superiority of the steroid-free
arm(TAC/DAC)overthereferencearm(TAC/STR).Kaplan-
Meier analysis was used to estimate rates of patient and graft
survival and survival over time to recurrence of HCV.
The signiﬁcance level was chosen as α = 10% (1-
sided). The chi-square test was used to compare diﬀerences
in adverse events between treatment arms. The last-value-
carried-forwardmethodwasusedforreplacementofmissing
laboratory values.
At investigator review of the results it became apparent
that some patients had received antiviral treatment for HCV
during the study. It was decided to perform post hoc analyses
of HCV viral load at month 12 excluding patients who had
taken antiviral medications for HCV. It was assumed that the
elimination of these patients from an analysis of the primary
endpoint would provide more information on the eﬀect of
the two protocols on HCV recurrence.
The full analysis set (FAS) population included all ran-
domized patients who received at least one dose of any im-
munosuppressivemedicationaccordingtotheassignedstudy
arm. The primary analysis set (PAS) comprised patients
included in the FAS and with an HCV viral load above the
limit of quantiﬁcation at baseline (≥615IU/m/L) to pro-
vide a population for analysis with active hepatitis C.
Primary endpoint results are presented for the PAS and FAS
populations, and the FAS is used for the presentation of all
other results.
3. Results
3.1. Recipient, Donor, and Transplant Characteristics. The
ﬂow of patient progress through the study is outlined in
Figure 1. Of 138 patients randomized to receive treatment,
135 were included in the FAS population. The rate of study
completion was lower in the TAC/DAC arm at 45% (30
of 67 patients) than the rate of 82% (56 of 68 patients)
in the TAC/STR arm. The main reason for premature
withdrawal in both arms was an adverse event (Figure 1).
Study discontinuation during week 1 was more common in
the TAC/DAC arm (12 of 37 withdrawn patients) than in the
TAC/STR arm (4 of 12 withdrawn patients). An erroneously
administered steroid bolus at transplantation was the reason
for 5 of the 6 protocol violations in the TAC/DAC group
and a patient in the TAC/STR arm violated the protocol for
receiving basiliximab. A baseline HCV viral load below the
limit of quantiﬁcation was documented in 17 patients in the
TAC/DAC arm and in 16 patients in the TAC/STR arm and
led to exclusion of these patients from the PAS. The PAS,
therefore, comprised 50 patients in the TAC/DAC and 52
patients in the TAC/STR arm. Of these, 19 patients (38%)
in the TAC/DAC arm and 35 patients (67%) in the TAC/STR
arm completed the study and were used in the analysis of the
primary endpoint.
Baseline patient demographics were broadly similar bet-
ween arms including the model for end-stage liver disease
(MELD) mean scores (Table 1). All patients presented with
a primary diagnosis of cirrhosis following hepatitis C in-
fection. Hepatocellular carcinoma was present in 29 of 67
patients (43%) in the TAC/DAC arm and 34 of 68 patients
(50%) in the TAC/STR arm at randomization. As would be
expected in this European sample, the most common HCV
g e n o t y p ei nb o t ha r m sw a s1 b .A l la l l o g r a f t sw e r er e c o v e r e d
fromdeceaseddonors.Agreaternumberoforganswerefrom
male donors in the TAC/DAC arm than in the TAC/STR: this
diﬀerence was not considered to aﬀect study results.
Patients in both arms received antiviral treatment during
the study in contradiction to the study protocol. This was 10
patients in the TAC/DAC arm and 21 in the TAC/STR arm
included in the FAS and 8 patients in the TAC/DAC arm
and 20 in the TAC/STR arm included in the PAS. Antivi-
ral treatment was administered to patients with biopsy-
proven recurrence to reduce the risk of early severe HCV
recurrence, which is associated with increased risk for graft
loss.
3.2. Immunosuppression. Mean tacrolimus trough levels in
both arms were well within the targeted range of 10–
15ng/mL up to day 42. Mean trough levels at month 12
were 7.6ng/mL in the TAC/DAC arm and 8.6ng/mL in
the TAC/STR arm, which were within the targeted range
of <10ng/mL. The mean (SD) daily dose of tacrolimus at
month 12 was 0.1 (0.06)mg/kg in the TAC/DAC arm and
0.05 (0.04)mg/kg in the TAC/STR arm.4 Journal of Transplantation
Patients randomized
TAC/STR TAC/DAC
Adverse events 16
Death 8
Protocol violation 6
Retransplantation             1
Withdraw of informed consent 0
Lost to follow up 1
Noncompliance 1
Other 4
Adverse event 5
Death 1
Protocol violation 1
Retransplantation 3
Withdrawal of informed consent 1
Lost to follow up 1
Noncompliance 0
Other 0
Included in FAS Included in FAS
Allocation
Analysis
Allocated to treatment (N = 68)
(n = 138)
Allocated to treatment (N = 70)
Not transplanted/no study medication (n = 2) Not transplanted/no study medication (n = 1)
(N = 67/100%) (N = 68/100%)
Completed: n = 30/44.8%
Prematurely discontinued study: n = 37/55.2%
Completed: n = 56/82.4%
Prematurely discontinued study:  n = 12/17.6%
Figure 1: Progress of liver transplant recipients through the phases of the randomized study comparing a tacrolimus-based protocol with
andwithoutsteroids.TherateofstudycompletionwaslowerwithTAC/DACthanwithTAC/STR.Mostcommonly,patientsintheTAC/DAC
arm prematurely discontinued the study due to an adverse event. TAC: tacrolimus; DAC: daclizumab; STR: steroids; FAS: full analysis set;
PAS: primary analysis set.
All patients in the TAC/DAC arm received one dose of
d a c l i z u m a ba n d5 2o f6 7( 7 8 % )r e c e i v e das e c o n dd o s e .
In violation of the protocol, 6 of 67 patients (9%) in the
TAC/DAC arm erroneously received steroid boluses perio-
peratively; the median (range) dose was 7.7 (1.9–9.8) mg/kg.
A few patients (1–3 patients at each scheduled assessment
visit)weretakingmaintenancesteroids.IntheTAC/STRarm,
56 of 68 patients were maintained on steroids at 3 months,
whichdecreasedto45patientsat6monthsandto17patients
at12months.Themediandailydoseofmaintenancesteroids
at 12 months was 0.04 (0.01–0.15) mg/kg. Pulse steroid
treatment for acute rejection was administered to 3 patients
intheTAC/DACarmandto10patientsintheTAC/STRarm.
3.3. HCV Viral Load. There was no signiﬁcant diﬀerence
between the treatment arms in HCV viral load at month 12
(Table 2). Results of the analysis using the PAS and the FAS
were similar.
AposthocanalysisofHCVviralloadthatwasperformed
on patients who had not received antiviral medications
during the study showed comparable median values for
HCV viral load for the PAS (Table 2). The diﬀerence in
medianvaluesbetweenthetreatmentarmsreachedstatistical
signiﬁcance for the FAS. In the interpretation of these results
it is important to note that analyses were performed post hoc
on patients completing the study and the number of study
completers was lower in the TAC/DAC arm.
3.4. HCV Recurrence. T h er a t eo fp a t i e n t sf r e eo fH C V
recurrence at 12 months was 19.1% with the TAC/DAC
steroid-free protocol and 13.8% with the TAC/STR protocol
(Kaplan-Meier method) with a signiﬁcant diﬀerence in
survival curves between treatments (95% CI, −0.105 to
0.211%; P = 0.020) (Figure 2). Early HCV recurrence at
month 3 was less common with the steroid-free protocol at
55% compared with 70% in the steroid arm.
Results of the post hoc analysis, in which liver biopsies
were centrally reviewed and HCV recurrence was censored
for antiviral treatment, favored the TAC/DAC immunosup-
pression protocol. The estimated rate of patients free of HCV
recurrence in this analysis was signiﬁcantly higher in the
TAC/DAC arm at 20.2% compared with 13.1% in TAC/STR
(95% CI, −0.091 to 0.234%; P = 0.022) (Table 3).
3.5. Fibrosis Stage. Protocol biopsies (performed at months
6 and 12) and nonprotocol biopsies were centrally reviewed
to assess ﬁbrosis score. As depicted in Table 3, there were no
diﬀerences between the treatment arms in the total meanJournal of Transplantation 5
Table 1: Baseline recipient and donor characteristics of the FAS population.
TAC/DAC TAC/STR
N = 67 N = 68
Recipient age, mean (SD) 53.1 (9.6) 55.3 (6.5)
Male, no. (%) 49 (73.1) 45 (66.2)
Mean (SD) MELD score 16.2 (6.3) 14.5 (6.1)
HCV genotype:
1 7 (12.1) 5 (8.3)
1a 8 (13.8) 4 (6.7)
1b 28 (48.3) 37 (61.7)
2 1 (1.7) 1 (1.7)
2a/c 1 (1.7) 0
3 4 (6.9) 5 (8.3)
3a 6 (10.3) 7 (11.7)
4 2 (3.4) 1 (1.7)
4a 1 (1.7) 0
HCV-RNA positive∗, no. (%) 50 (84.7) 55 (94.8)
Serum HCV-RNA, median (min; max) IU/mL 5.05 (0.95; 6.61) 5.09 (0.95; 6.12)
Donor age, mean (SD) years 49.1 (19.0) 50.6 (19.3)
Donor age <60 years, mean (SD) years 41 (61.2) 47 (64.7)
Donor age ≥60 years, mean (SD) years 26 (38.8) 24 (35.3)
Donor sex, male, no. (%) 43 (64.2) 32 (47.1)
Traumatic cause of donor death, no. (%) 21 (33.3) 20 (30.8)
Non-traumatic cause of donor death, no. (%) 42 (66.7) 45 (69.2)
Ischemic time, mean (SD), hours 8.8 (3.3) 8.0 (3.0)
Donor/recipient CMV serological status:
Donor +/recipient −, no. (%) 8 (11.9) 6 (8.8)
ABO identical, no. (%) 66 (98.5) 64 (94.1)
SD: standard deviation; HCV: hepatitis C virus; MELD: mean model for end-stage liver disease; CMV: cytomegalovirus.
∗HCV-RNA above the limit of quantiﬁcation at baseline.
Table 2: Measurement of median (min; max) HCV viral load at month 12 in patients completing the study∗.
N TAC/DAC N TAC/STR
Median (min; max) HCV viral load,
IU/mL; PAS 19 5.46 (0.95; 6.54) 35 5.91 (0.95; 6.89)
Median (min; max) HCV viral load,
IU/mL; PAS (no viral) treatment
during study
14 5.77 (3.45; 6.54) 20 5.99 (5.32; 6.89)
Median (min; max) HCV viral load,
IU/mL; FAS 25 4.52 (0.95; 6.4) 46 5.9 (0.95; 6.89)
Median (min; max) HCV viral load,
IU/mL; FAS (no viral) treatment
during study
20 5.25 (0.95; 6.54)† 26 5.99 (3.47; 6.89)
PAS: Primary analysis set: All randomized and transplanted subjects with baseline viral load above the limit of quantiﬁcation.
FAS: Full analysis set: All randomized and transplanted patients
∗Patients completing the study with data available within ± 14 days of day 365.
†P = 0.024 Wilcoxon rank sum test for superiority of TAC/DAC over TAC/STR.
modiﬁed ﬁbrosis staging score; mean scores were <2i nb o t h
arms. More cases of severe ﬁbrosis, as evidenced by a score
of ≥4, were assessed in the TAC/DAC arm (4 of 35biopsies)
compared with the TAC/STR arm (0 of 54biopsies). There
was no clinically relevant diﬀerence between the treatment
armsinmeantotalmodiﬁedHAIgradingscoreat12months
(Table 3).
3.6. Patient and Graft Survival. The overall estimated rate
of patient survival (Kaplan-Meier method) was signiﬁcantly6 Journal of Transplantation
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Figure 2: Estimated rate of patients free from recurrence of HCV
Infection (Kaplan-Meier Method) at 12 months as conﬁrmed by
central biopsy. Freedom from HCV recurrence at 12 months was
19.1% with the TAC/DAC steroid-free protocol and 13.8% with
the TAC/STR protocol (Kaplan-Meier method) with a signiﬁcant
diﬀerence in survival curves between treatments (95% CI, −0.105
to0.211%;P = 0.020, Wilcoxon Gehan test).Protocolbiopsies were
performed at months 6 and 12 accounting for the higher number
of events reported at these time points. TAC: tacrolimus; DAC:
daclizumab; STR: steroids.
lower in the TAC/DAC arm (95% CI, −0.227 to −0.019%;
P = 0.025) (Table 3).
The estimated rate of graft survival was numerically
lower in the TAC/DAC arm (Table 3) .T h er a t eo fg r a f tl o s s
was 19.4% in the TAC/DAC arm (13 of 67 patients) and
8.8% in the TAC/STR arm (6 of 68 patients). Patient death
accounted for 11 of the 13 grafts lost in the TAC/DAC arm
and for 3 of the 6 grafts lost in the TAC/STR arm.
There were 11 patient deaths in the TAC/DAC arm; 8
deaths occurred during the study and 3 after premature
withdrawal. The causes of death were HCV recurrence (3
patients), cardiovascular complications (5 patients), surgical
complications (2 patients), and infection (1 patient). Spe-
ciﬁcally, cardiac complications were myocardial ischemia,
cardiac tamponade, cerebral hemorrhage, cardiac failure
(identiﬁedasnotorunlikelyrelatedtostudydrug),andcere-
brovascular accident (identiﬁed as possibly related to study
drug). There were 3 patient deaths in the TAC/STR arm, 1
death during the study and 2 after study withdrawal. The
causes of death were HCV recurrence, surgical complica-
tions, and infection (each 1 patient).
3.7. Biopsy-Proven Acute Rejection. The overall frequency
of BPAR was signiﬁcantly lower in the TAC/DAC than in
the TAC/STR arm (P = 0.048, chi-square test) (Table 3).
Estimated freedom from BPAR (Kaplan-Meier method) was
numerically but not signiﬁcantly higher with TAC/DAC
(78.4%) than with TAC/STR (66.1%) (95% CI, −0.042 to
0.287%) (Table 3).
Histological ﬁndings showed that the majority of rejec-
tionswereclassiﬁedasmild(BanﬀI)inbothtreatmentarms:
8of11(11.9%)intheTAC/DACarmand14of21(20.6%)in
the TAC/STR arm. One rejection in the TAC/DAC arm was
c l a s s i ﬁ e da ss e v e r e( B a n ﬀ III).
3.8. Renal Function. Baseline serum creatinine was compa-
rable. Renal function at 12 months, assessed using calculated
creatinine clearance (Cockroft-Gault method) and serum
creatinine, was comparable between the two arms. Mean
(SD) creatinine clearance was 72.2 (27.3)mL/min in the
TAC/DAC arm and 74.7 (30.6)mL/min in the TAC/STR
arm. Mean serum creatinine in the TAC/DAC arm was 128.4
(68.8)μmol/L and 110.8 (59.7)μmol/L in the TAC/STR arm.
3.9. Adverse Events. A summary of the adverse event proﬁle
for the two treatment arms is presented in Table 4.A n
adverse event occurred in 91% of TAC/DAC and 97% of
TAC/STR patients. Serious adverse events occurred in two-
thirds of patients, most commonly infection. There was a
signiﬁcantly lower incidence of hepatitis C reported as an
adverseeventintheTAC/DACarmthanintheTAC/STRarm
and a signiﬁcantly higher incidence of thrombocytopenia in
the TAC/DAC arm than in the TAC/STR arm.
The number of patients discontinuing the study due to a
treatmentemergentadverseeventwasthreefoldhigherinthe
TAC/DAC arm than in the TAC/STR arm. In the TAC/DAC
arm, 16 of 67 patients (24%) discontinued the study
compared with 5 of 68 patients (7.4%) in the TAC/STR arm.
Malignancies occurred with an incidence of 4.5% (3 of
67 patients) in the TAC/DAC arm and 3% (2 of 68 patients)
in the TAC/STR arm. These were 2 cases of hepatocellular
carcinoma and 1 case of uterine cancer in the TAC/DAC arm
and 1 basal cell carcinoma and 1 peritoneal carcinoma in the
TAC/STR arm. The incidence of new onset diabetes mellitus
after transplantation was 1.5% (1 patient) in the TAC/DAC
arm and 6% (4 patients) in the TAC/STR arm.
4. Discussion
Theresultsofthisstudyshowedthatthesteroid-freeprotocol
in comparison to the protocol with steroids had a negligible
impact on viral HCV RNA values at 12 months. Results of
thepost hoc analysis, whichexcluded patients whohadtaken
antiviral medications for treatment of HCV, indicated an
even smaller between-treatment diﬀerence in viral load in
the primary analysis set but a signiﬁcant diﬀerence in the full
analysis set.
This study, despite its limitations, is one of a few
randomized controlled multicenter studies to prospectively
analyze HCV viral load and disease recurrence using a
steroid-free protocol. While we did not observe an impact
of this experimental treatment protocol on viral load, we
did ﬁnd that the estimated rate of patients remaining free
of HCV recurrence was slightly better with the steroid-
free protocol. The exclusion of patients who had received
antiviral treatment during the study did not aﬀect rates of
HCV recurrence in either arm or the between-treatment arm
diﬀerence in rates. As reported in other comparative trials in
HCV-positive patients [10, 15, 21], we observed a tendency
for earlier recurrence in the steroid arm. The higher numberJournal of Transplantation 7
Table 3: Secondary study endpoints-full analysis set.
TAC/DAC TAC/STR
NN
Estimated rate of patients free of
HCV recurrence∗,% 67 19.1 68 13.8
Estimated rate of patients free of
HCV recurrence, censored for
antiviral treatment, %
67 20.2 68 13.1
Modiﬁed ﬁbrosis staging†, mean
score (SD) 35 1.9 (1.2) 54 1.6 (0.7)
Stage 0, no. (%) 0 1 (1.7)
Stage 1, no. (%) 18 (41.9) 25 (43.1)
Stage 2, no. (%) 10 (23.3) 22 (37.9)
Stage 3, no. (%) 3 (7.0) 6 (10.3)
Stage 4, no. (%) 2 (4.7) 0
Stage 5, no. (%) 2 (4.7) 0
Stage 6, no. (%) 0 0
Modiﬁed HAI grading‡, mean total
score (SD) 35 6.7 (2.7) 54 6.5 (2.5)
Patient survival§, % 67 83.1 68 95.5
Graft survival, % 67 80.1 68 91.1
Biopsy-proven acute rejection¶,n o .
(%) 67 11 (16.4) 68 21 (30.9)
Treatment resistant, no. (%) 4 (6.0) 2 (2.9)
Treatment sensitive, no. (%) 3 (4.5) 7 (10.3)
Spontaneous resolution 4 (6.0) 14 (20.6)
Estimated freedom from
biopsy-proven acute rejection¶,% 67 78.4 68 66.1
HCV: hepatitis C virus; SD: standard deviation; HAI: histologic activity index.
∗95% CI, −0.105 to 0.211%; P = 0.020, Wilcoxon Gehan test.
†Worst ﬁbrosis staging per patient using the modiﬁed scoring system of Ishak et al. [19] in which a score of 6 is complete ﬁbrosis. Central evaluation of
nonprotocol biopsies and protocol biopsies (at 6 and 12 months) was used to assess ﬁbrosis score.
‡Worst histological HCV grading per patient using the modiﬁed HAI grading [14]. Central evaluation of nonprotocol biopsies and protocol biopsies (at 6
and 12 months) was used to assess HAI grading.
§95% CI (Greenwood formula) for the diﬀerence in 12-month patient survival was −0.227 to −0.019%, P = 0.025.
¶Local evaluation of biopsies. P = 0.048, chi-square test comparing the numbers of patients.
of patients in that arm who received steroid pulse treatments
for acute rejection might have contributed to this result.
Conversely,weobservedatendencyformoreadvancedﬁbro-
sis occurring with TAC/DAC. Wiesner et al. [1] recommend
yearly biopsies beyond 5 years followingtransplantation to
determine histological progression of HCV infection. A
longer-time span to register ﬁbrotic changes and a more
detailed analysis of ﬁbrosis progression might have yielded
more clinically relevant comparative data of longer term
outcomes with the two treatment protocols.
Using daclizumab in place of steroids had no compro-
mising eﬀect on eﬃcacy as shown by the lower incidence
of BPAR with TAC/DAC than TAC/STR. Adding MMF
to the steroid-free protocol may have provided higher
immunocoverage with lower BPAR incidence as reported in
a similar study using a triple-drug steroid-free protocol [21].
We acknowledge that many features of mild rejection and
HCV recurrence are shared and that mild rejection in the
presence of HCV might be diﬃcult to distinguish from HCV
recurrence alone.
There were unexpected diﬀerences between the treat-
ment arms in patient tolerability of treatment and the
incidence of premature withdrawal. Although adverse events
occurred with a similar frequency in the two treatment arms,
anadverseeventwasmorecommonlythecauseofpremature
study withdrawal in the steroid-free arm. No single type of
adverse event accounted for the higher number of dropouts.
In a parallel arm randomized trial with treatment interven-
tions similar to those we applied, premature study discontin-
uationswerealsohigherinthetacrolimus+daclizumabthan
in the tacrolimus + steroids arm [17]. The higher incidence
of thrombocytopenia in the TAC/DAC arm is diﬃcult to
explain as other consequences of bone marrow suppression
(pancytopenia and leukopenia) were higher in the TAC/STR
arm and incidences of anemia were similar between treat-
ment arms. Lower rates of hepatitis C reported as an adverse8 Journal of Transplantation
Table 4: Incidence of adverse events occurring in ≥10% in either
arm of full analysis set and with a signiﬁcant diﬀerence between
treatment arms, no. (%).
TAC/DAC TAC/STR
N = 67 N = 68
Hepatitis C∗ 28 (41.8) 43 (63.2)
Hyperglycemia 9 (13.4) 13 (19.1)
Hyperkalemia 8 (11.9) 7 (10.3)
Anemia 22 (32.8) 21 (30.9)
Thrombocytopenia† 19 (28.4) 6 (8.8)
Leukopenia 10 (14.9) 15 (22.1)
Pancytopenia 4 (6.0) 7 (10.3)
Renal failure 20 (29.9) 23 (33.8)
Acute renal failure 7 (10.4) 6 (8.8)
Diarrhea 9 (13.4) 14 (20.6)
Ascites 3 (4.5) 8 (11.8)
Hypertension 17 (25.4) 20 (29.4)
Hypotension 8 (11.9) 9 (13.2)
Pleural eﬀusion 12 (17.9) 15 (22.1)
Headache 8 (11.9) 8 (11.8)
Tremor 9 (13.4) 6 (8.8)
Peripheral edema 7 (10.4) 10 (14.7)
Insomnia 7 (10.4) 5 (7.4)
Back pain 8 (11.9) 9 (13.2)
Pruritus 5 (7.5) 7 (10.3)
Not presented are adverse events related to the transplanted allograft or
procedural complications.
∗P = 0.016; †P = 0.004 (Fisher’s exact test comparing the number of
patients).
event in the TAC/DAC arm may indicate a potential safety
beneﬁt of this protocol over one with steroids.
Patient survival was lower, albeit not signiﬁcantly, in the
steroid-free than in the steroid arm but is comparable to
results reported from another steroid-free clinical trial [15].
We cannot provide an explanation as to why this occurred.
We could ﬁnd no demographic or comorbidity factors,
or common events leading to or causing death or serious
adverse events to account for this diﬀerence. The higher
number of patient deaths caused by cardiac events in the
steroid-freearmcouldbeattributedtochance.Contrastingly,
patient survival in the steroid arm was 96%, which is
exceptionally good considering that the study population
was HCV positive. This survival rate is higher than the rate
of 88.4% for unadjusted 1-year patient survival (deceased
donor) reported in the 2009 OPTN/SRTR Annual Report on
the status of liver transplantation [22].
We urge caution in the interpretation of these results
for several reasons. The ﬁrst is the low number of patients
providing data for the primary endpoint; this aﬀected the
statistical power of the study generating inconclusive results.
Secondly, only the post hoc analysis, which is biased due to
the elimination of patients treated with antiviral agents and
limited because of the post hoc method, revealed superiority
of the steroid-free protocol over the reference protocol in
impacting on HCV viral load in HCV-positive patients.
It is diﬃcult to recommend a steroid-free protocol for
HCV-positive patients based on study results. The impact of
this protocol on HCV viral load at one year wasinsigniﬁcant,
and although there was a tendency for later HCV recurrence
and lower incidences of rejection, we also observed a
higher dropout rate and a lower patient survival rate with
tacrolimus and daclizumab compared to tacrolimus and
steroids. A study of longer duration could provide important
clinical information on the relationship between type of
treatment protocol and viral load, HCV recurrence, and
ﬁbrosis progression.
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